Phospho-AKT1 (Ser473) Antibody - #AF8355

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(14)   (12)  
产品: 磷酸化 AKT1 (Ser473) 抗体
货号: AF8355
描述: Rabbit polyclonal antibody to Phospho-AKT1 (Ser473)
应用: WB IF/ICC
文献验证: WB
反应: Human, Mouse, Rat, Monkey
预测: Pig, Zebrafish, Bovine, Horse, Dog, Chicken, Xenopus
蛋白号: P31749
RRID: AB_2840417

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1500 现货
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:1000-3000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat, Monkey
克隆:
Polyclonal
特异性:
Phospho-AKT1 (Ser473) Antibody detects endogenous levels of AKT1 only when phosphorylated at Ser473.
RRID:
AB_2840417
引用格式: Affinity Biosciences Cat# AF8355, RRID:AB_2840417.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

AKT 1; AKT; AKT1; AKT1_HUMAN; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-Akt; RAC Alpha; RAC; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha;

抗原和靶标

免疫原:

A synthesized peptide derived from human AKT1 around the phosphorylation site of Ser473.

基因/基因ID:
AKT1(207)

研究领域

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species.   (View pathway)

· Organismal Systems > Circulatory system > Adrenergic signaling in cardiomyocytes.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Nervous system > Dopaminergic synapse.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

· Organismal Systems > Digestive system > Carbohydrate digestion and absorption.

文献引用

1). American ginseng improves ovarian dysfunction through miR-151-5p activation of BDNF/AKT/BCl-2/Bax signaling pathway in premature ovarian failure model rats: protein macromolecules and expression. International journal of biological macromolecules, 2025 (PubMed: 40280046) [IF=7.7]
2). Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33524788) [IF=6.9]
3). p75NTR-/- mice exhibit an alveolar bone loss phenotype and inhibited PI3K/Akt/β-catenin pathway. CELL PROLIFERATION, 2020 (PubMed: 32215984) [IF=5.9]

Application: WB    Species: Mice    Sample: mandibular RNA and protein

FIGURE 3 PI3K/Akt pathway is downregulated in p75NTR−/− EMSCs. (A) Cluster analysis showed the differentially expressed genes between WT and p75NTR−/− EMSCs after cultured in osteogenic induction medium for 7 d. (B) Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis of RNA-seq data. The top ten enriched pathways are shown. (C) The expression levels of PI3K, p-PI3K, Akt, p-Akt and β-catenin were detected by Western blot analysis during osteogenic induction. Grayscale analysis was performed, and (D) the levels of β-catenin proteins were expressed relative to the levels of GAPDH, (E) phosphorylation of PI3K and Akt were analysed, and the results were represented as fraction of the control. (F) The expression levels of PI3K, Akt and β-catenin were detected by real-time PCR normalized to GAPDH. All experiments were repeated at least three times. adjusted P-value (Padj) < .05, *P < .05, ***P < .001, ns = no significant difference
4). Protect Effects of Perilla Seed Extract and Its Active Ingredient Luteolin Against Inflammatory Bowel Disease Model via the PI3K/AKT Signal Pathway In Vivo and In Vitro. International journal of molecular sciences, 2025 (PubMed: 40332054) [IF=5.6]

Application: WB    Species: Mouse    Sample:

Figure 6. The effect of PSE on PI3K/AKT1 pathway protein in intestinal tissue. The experimental groups were divided into four groups: (i) CON (drinking water), (ii) PBS (PBS), (iii) LPS (3.5 mg/kg BW), (iv) PSE (3.5 mg/kg and PSE 100 mg/kg/d) n = 3. Representative Western blot images (A) and quantification of AKT1 (B), p-AKT1 (C), p-AKT1/AKT1 (D), PI3K (E), p-PI3K (F), p-PI3K/PI3K (G) protein expression. PSE inhibits PI3K and AKT1 phosphorylation. Data are expressed as mean ± SEM. ## p < 0.01 vs. control group; * p < 0.05, ** p < 0.01 vs. LPS control group.
5). Hu'po Anshen Decoction Accelerated Fracture-Healing in a Rat Model of Traumatic Brain Injury Through Activation of PI3K/AKT Pathway. Frontiers in pharmacology, 2022 (PubMed: 35924045) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 9. HPASD promoted the expressions of osteogenic factors in the rat model of traumatic brain injury by activating PI3K/AKT pathway. (A) The mRNA expression levels of osteogenic factors, COL1A1, RUNX2, BMP2, Aggrecan, and inflammation-related factor, MMP13 were evaluated by real-time PCR (B) Representative western blots and quantitative analysis of the VEGFA, COL1A1, RUNX2, BMP2, Aggrecan, MMP13, PI3K p85, p-AKT (Thr308), p-AKT (Ser473), and AKT in the callus tissues of TBI rats in each group. *p < 0.05, **p < 0.01 vs. Fracture-only group; ▲p < 0.05, ▲▲p < 0.01 vs. Fracture + TBI group [unpaired Student’s t-test].
6). Buxuhuayu Decoction Accelerates Angiogenesis by Activating the PI3K-Akt-eNOS Signalling Pathway in a Streptozotocin-Induced Diabetic Ulcer Rat Model. JOURNAL OF ETHNOPHARMACOLOGY, 2021 (PubMed: 33581257) [IF=4.8]

Application: WB    Species: Rat    Sample:

Fig. 13. The protein expressions of p-PI3K, p-AKT1, and p-eNOS by Western blot at 7 days after administration. n = 3 for each group. Quantifications of the bands (b–d) (mean±SEM). Compared with CG, *P < 0.05 and **P < 0.01; Compared with MG, #P < 0.05, ##P < 0.01, &P < 0.05 and &&P < 0.01.
7). Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells. BMC cancer, 2024 (PubMed: 38200409) [IF=3.8]
8). The increased expression of cytokeratin 13 leads to an increase in radiosensitivity of nasopharyngeal carcinoma HNE-3 cells by upregulating ERRFI1. IUBMB life, 2023 (PubMed: 37070291) [IF=3.7]

Application: WB    Species: human    Sample: HNE-3 cells

FIGURE 3 CK13 exerts anticancer effects by upregulating ERRFI1. (a and b) Western blotting (WB) and qPCR were used to measure ERRFI1 expression after transient transfection of CK13 overexpression plasmid or control plasmid. **p 
9). LAIR-1 overexpression inhibits epithelial-mesenchymal transition in osteosarcoma via GLUT1-related energy metabolism. World journal of surgical oncology, 2020 (PubMed: 32563267) [IF=3.2]

Application: WB    Species: Human    Sample: OS cells

Fig. 3 LAIR-1 overexpression in HOS cells inhibits the expression of EMT-associated transcription factors by decreasing p-Foxo1 expression. a Expression of Twist1 in untreated HOS cells (Blank) and corresponding LV-NC- and LV-LAIR-1-overexpressing transfectants was analyzed by qPCR. b Twist1, N-cadherin, p-Foxo1, total Foxo1, p-Akt, and total Akt expression were analyzed by western blotting in blank, LV-NC-overexpressing, and LV-LAIR-1-overexpressing OS cells. c Twist1, p-Foxo1, and total Foxo1 expression were analyzed by western blotting in blank, negative control (NC) siRNA, and Foxo1 siRNA (siFoxo1)-transfected OS cells. Representative immunofluorescence staining for Twist1 (d) and Foxo1 (e) in HOS cells (left). Cell nuclei were stained with DAPI (blue). Scale bar = 20 μm. The statistical data for the images are shown in histograms (right). *P < 0.05, **P < 0.01. Results represent at least three independent experiments.
10). LAIR-1 overexpression inhibits osteosarcoma epithelial-mesenchymal transition via GLUT1-related energy metabolism. World Journal of Surgical Oncology, 2020 (PubMed: 32563267) [IF=3.2]

Application: WB    Species: Human    Sample: OS cells

Fig. 3 LAIR-1 overexpression in HOS cells inhibits the expression of EMT-associated transcription factors by decreasing p-Foxo1 expression. a Expression of Twist1 in untreated HOS cells (Blank) and corresponding LV-NC- and LV-LAIR-1-overexpressing transfectants was analyzed by qPCR. b Twist1, N-cadherin, p-Foxo1, total Foxo1, p-Akt, and total Akt expression were analyzed by western blotting in blank, LV-NC-overexpressing, and LV-LAIR-1-overexpressing OS cells. c Twist1, p-Foxo1, and total Foxo1 expression were analyzed by western blotting in blank, negative control (NC) siRNA, and Foxo1 siRNA (siFoxo1)-transfected OS cells. Representative immunofluorescence staining for Twist1 (d) and Foxo1 (e) in HOS cells (left). Cell nuclei were stained with DAPI (blue). Scale bar = 20 μm. The statistical data for the images are shown in histograms (right). *P < 0.05, **P < 0.01. Results represent at least three independent experiments.
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.